Navigation Links
Dynasil Corporation of America Reports Third Quarter Fiscal 2013 Financial Results

WATERTOWN, Mass., Aug. 12, 2013 /PRNewswire/ -- Dynasil Corporation of America (NASDAQ: DYSL), a leading developer of sensing, detection and analysis technology for homeland security, medical and industrial applications, today announced financial results for the fiscal 2013 third quarter ended June 30, 2013. 

Dynasil reported a net loss for the quarter of ($366,000) or ($0.02) per share, compared with net loss of ($332,000), or ($0.02) per share, for the quarter ended June 30, 2012.  The third quarter results include initial sales of the Company's new Navigator 2.0™ medical probe for cancer surgery which was approved for sale and began shipping in late May 2013.  "I am happy to report that our updated Navigator 2.0™ medical probe was approved for sale in the United States and we began shipping this refreshed product," said Dynasil Chairman and Interim CEO Peter Sulick.  "We are currently pursuing the CE Mark, necessary to meet European Union requirements, and anticipate international sales will begin in the near future."

Net revenue for the third quarter of fiscal 2013 declined $0.8 million to $11.3 million, compared with $12.1 million for the third quarter of fiscal 2012.  Revenue declined in the Contract Research and Optics segments in the quarter while the Instruments segment remained largely flat as compared with the same period last year.
Gross profit for the third quarter of 2013 declined slightly to $4.8 million from $5.0 million for the same period in 2012 although gross margins increased to 43% in the quarter compared to 41% for the third quarter of fiscal 2012. 

Operating expenses for the three months ended June 30, 2013 were $5.0 million, a decrease of $81,000 compared to the same period in 2012.  The decrease was a result of the reduced expenditures associated with the product refresh within the Instruments segment in 2012 which was largely offset by increased General and Administrative expenses.

The Company continues to be in default of certain financial covenants set forth in the terms of its outstanding indebtedness as of June 30, 2013.  However, the Company has made all principal and interest payments due its senior lender through August 12, 2013, the date of this earnings release.  The Company has accrued but not remitted interest payments to its subordinated lender since February, 2013.
Management is currently evaluating potential transactions involving the sales of divisions and/or product lines which, if consummated, would result in additional debt principal payments to the bank.  The Company cannot, however, predict when or whether a resolution of this situation will be achieved.

Quarterly Business HighlightsThe Company received regulatory approval for its updated medical probe for cancer surgery in the third quarter for the United States market and began shipping this product.  The Company is continuing to pursue CE mark approval for this product internationally.  In addition, the Company is evaluating preliminary test results received on its updated lead paint analyzer product while also evaluating strategic alternatives associated with this product.

The Company continues to pursue various commercialization opportunities arising from technologies developed within our Contract Research segment.  "One of our leading commercialization efforts involve our CLYC crystals, which are now being sold commercially," stated Mr. Sulick. "We continue our efforts to further improve the size and quality of this product as well as develop new applications."Additionally, the Company has prepared a separate business and financing plan for one of the biomedical technologies.  Our intention is to spin out the tissue sealant technology into an independent entity in which the Company would retain a substantial interest.  This would enable us to raise funds specifically for this venture and recruit additional expertise to help advance the technology.  In June, 2013, our senior lender agreed to release the intellectual property and related collateral in connection with the spin-out in exchange for an additional debt payment of $300,000.  As a result, we are proceeding with plans to establish the joint venture and raise outside funding to support the joint venture; however, there can be no assurance that we will be able to raise the funding necessary for the transaction or consummate this transaction at any future time.

The Company has no conference calls scheduled at this time.

About Dynasil
Dynasil Corporation of America (NASDAQ: DYSL) develops and manufactures detection and analysis technology, precision instruments and optical components for the homeland security, medical and industrial markets.  Combining world-class technology with expertise in research and materials science, Dynasil is commercializing products including dual-mode radiation detection solutions for Homeland Security and commercial applications, probes for medical imaging and sensors for non-destructive testing.  The Company is building a relationship with the Mayo Clinic to develop early-stage opportunities such as advanced biomedical technologies. Dynasil has an impressive and growing portfolio of issued and pending U.S. patents.  The Company is based in Watertown, Massachusetts, with additional operations in Mass., Minn., NY, NJ and the United Kingdom. More information about the Company is available at

Forward-looking Statements This news release may contain forward‑looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management, including, without limitation, our expectations regarding results of operations, the commercialization of our products including our dual mode detectors, the adequacy of our current financing sources to fund our current operations, our growth initiatives, our capital expenditures, regulatory approvals and the strength of our intellectual property portfolio.  These forward-looking statements may be identified by the use of words such as "may," "could," "expect," "estimate," "anticipate," "continue" or similar terms, though not all forward-looking statements contain such words.  The actual results of the future events described in such forward‑looking statements could differ materially from those stated in such forward‑looking statements due to a number of important factors. These factors that could cause actual results to differ from those anticipated or predicted include, without limitation, our ability to resolve our current default under our outstanding indebtedness,  our ability to develop and commercialize our products, including obtaining regulatory approvals, the size and growth of the potential markets for our products and our ability to serve those markets, the rate and degree of market acceptance of any of our products, our ability to address our material weaknesses in our internal controls, general economic conditions, costs and availability of raw materials and management information systems, our ability to obtain and maintain intellectual property protection for our products, competition, the loss of key management and technical personnel, our ability to obtain timely payment of our invoices to governmental customers, litigation, the effect of governmental regulatory developments, the availability of financing sources, our ability to identify and execute on acquisition opportunities and integrate such acquisitions into our business, and seasonality, as well as the uncertainties set forth in the Company's 2012 Annual Report on Form 10‑K, as amended on February 14, 2013, including the risk factors contained in Item 1a, the Company's Quarterly Reports on Form 10-Q filed on February 13, 2013 and May 15, 2013 and from time to time in the Company's other filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

 Dynasil Corporation of America and SubsidiariesConsolidated Balance SheetsJune 30, 2013September 30, 2012ASSETS(Unaudited)Current AssetsCash and cash equivalents

$2,778,365$3,414,880Accounts receivable, net

3,995,5525,475,142Costs in excess of billings and unbilled receivables

1,558,4071,735,798Inventories, net of reserves

3,344,7443,271,700Deferred tax asset

126,187126,187Prepaid expenses and other current assets

1,370,2641,334,649Total current assets

13,173,51915,358,356Property, Plant and Equipment, net

4,705,9114,984,150Other AssetsIntangibles, net


6,136,12810,254,160Deferred financing costs, net

127,036165,457Total other assets

Total Assets

$27,748,771$37,465,428LIABILITIES AND STOCKHOLDERS' EQUITYCurrent LiabilitiesCurrent portion of long-term debt

$10,583,334$11,984,492Capital lease obligations, current

108,184-0-Accounts payable

2,629,0542,416,397Deferred revenue

542,896694,672Accrued expenses and other liabilities

2,112,7912,809,580Total current liabilities

15,976,25917,905,141Long-term LiabilitiesCapital lease obligations, net of current portion

274,972-0- Pension liability

342,848345,443Deferred tax liability

227,063371,256Total long-term liabilities

844,883716,699Stockholders' Equity

10,927,62918,843,588Total Liabilities and Stockholders' Equity$27,748,771$37,465,428 

 Dynasil Corporation of America and Subsidiaries
Consolidated Statement of OperationsThree Months EndedNine Months EndedJune 30,June 30,2013201220132012Net revenue$11,322,342$12,082,037$32,360,147$36,513,342Cost of revenue6,494,4637,097,37818,113,83021,317,392Gross profit4,827,8794,984,65914,246,31715,195,950Operating expenses:Sales and marketing expenses418,318444,3691,384,7391,289,131Research and development expenses499,732721,2791,710,0902,343,119General and administrative expenses4,125,3363,958,36212,043,22412,116,439Impairment of goodwill and long-lived assets  -0-   -0- 6,763,072  -0- Total operating expenses5,043,3865,124,01021,901,12515,748,689Loss from operations(215,507)(139,351)(7,654,808)(552,739)Interest expense, net181,773140,246545,690386,877Loss before income taxes(397,280)(279,597)(8,200,498)(939,616)Income tax provision (benefit)(30,920)52,303(213,065)(393,044)Net loss($366,360)($331,900)($7,987,433)($546,572)Net loss($366,360)($331,900)($7,987,433)($546,572)Other comprehensive loss:Foreign currency translation(45)(107,330)(245,666)(29,138)Total comprehensive loss($366,405)($439,230)($8,233,099)($575,710)Basic net loss per common share($0.02)($0.02)($0.54)($0.04)Diluted net loss per common share($0.02)($0.02)($0.54)($0.04)Weighted average shares outstandingBasic14,859,89914,275,29314,767,40114,878,360Diluted14,859,89914,275,29314,767,40114,878,360 

Patty Kehe
Corporate Secretary
Dynasil Corporation of America
Phone: (617) 668-6855

SOURCE Dynasil Corporation of America
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Corporation Reports Second Quarter 2013 Financial Results
2. Celsion Corporation Reports Second Quarter 2013 Financial Results and Provides HEAT Study Update
3. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2013 Results
4. DURECT Corporation Announces Second Quarter 2013 Financial Results and Update of Programs
5. Psychemedics Corporation Announces Top Revenue Quarter
6. Celsion Corporation to Hold Second Quarter 2013 Financial Results Conference Call on Thursday, August 8, 2013
7. Comprehensive Care Corporation Signs Agreement With A National Leader In Pharmacy Benefit Management
8. Luminex Corporation Reports Second Quarter 2013 Results
9. CVS Caremark Corporation To Hold Second Quarter 2013 Conference Call
10. MGC Diagnostics Corporation to Present at the Southern California Investor Conference on Thursday, August 8, 2013
11. FMC Corporation overtar ledende høy-rene Omega-3 konsentratprodusent Epax AS
Post Your Comments:
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association ... Featuring a collection of specialty vendors and unique items from across the nation, this ... health and wellness services offered by the VNA. The boutique will be open ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
Breaking Medicine News(10 mins):